Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Approves Long-Term Incentive Award for CEO
Summary
On May 21, 2025, Thermo Fisher Scientific Inc.'s Board of Directors approved a 5-year cliff vesting performance-based restricted stock units for its CEO, Marc N. Casper, to secure his leadership through at least May 2030 and drive substantial returns to shareholders. The award, valued at approximately $60 million, is designed to incentivize total shareholder return (TSR) outperformance and aligns with market compensation practices.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement